Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension

Stopped early · Phase 1/Phase 2

Conditions studied: Sickle Cell Disease, Pulmonary Hypertension

In brief

The goal of this study is to test the hypothesis that hydroxyurea is effective for the specific treatment of secondary pulmonary hypertension found on screening in children and young adults with sickle cell disease.

Key facts

Study ID

NCT00350844

Run by

Ann & Robert H Lurie Children's Hospital of Chicago

People needed

6

Starts

2006-07-01

Expected to finish

2008-06-01

Last updated by the study team

2019-08-06

Who can join

Age: 10 and older, up to 25. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 10 and 25 years old
• Sickle cell disease with hemoglobin SS, SC or S-B\^0 thalassemia confirmed on hemoglobin electrophoresis
• Tricuspid regurgitant jet velocity (TRJV) equal to or greater than 2.5 m/sec on 2 baseline Doppler echocardiograms at least 3 months apart

You may not qualify if…

• Patients already being treated with hydroxyurea
• Patients on a chronic transfusion protocol
• Patients with evidence of hepatic (alanine aminotransferase [ALT] equal to or greater than 2 SD above normal) or renal dysfunction (creatinine [Cr] equal to or greater than 2 SD above normal)
• Patients who are pregnant
• Patients with documented causes of severe pulmonary hypertension other than from SCD

Where it is running

• Ann & Robert H Lurie Children's Hospital of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.